Compare Novo Nordisk A/S (NVO) vs Direxion Daily TSLA Bull 2X Shares (TSLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Direxion Daily TSLA Bull 2X Shares — how do they compare? Novo Nordisk A/S trades at $46.26 (market cap $207.85B), while Direxion Daily TSLA Bull 2X Shares trades at $8.01. The key difference: Novo Nordisk A/S pays a 3.81% dividend while Direxion Daily TSLA Bull 2X Shares pays none, and Novo Nordisk A/S is trading nearer its 52-week high, Direxion Daily TSLA Bull 2X Shares nearer its low. Which is the better fit depends on your goals.
| NVO | TSLL | |
|---|---|---|
Market Cap | $207.85B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $63.98 | $23.03 |
52-Week Low | $35.29 | $6.74 |
Enterprise Value | $222.55B | — |
Dividend Yield | 3.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
TSLL (Direxion Daily TSLA Bull 2X Shares ETF) trades at $8.15, down 0.73% on the day, with technical indicators showing a bearish trend. The ETF, which aims to deliver twice Tesla's daily returns, faces challenges as recent news highlights volatility risks for leveraged Tesla investments. Key support sits at $8 with resistance at $9, while RSI levels suggest mixed momentum signals.
The outlook remains cautious given the bearish technical signals and leveraged structure amplifying Tesla's volatility. Investment opportunities exist for short-term traders betting on Tesla rebounds, but risks include magnified losses during downturns and the structural decay of daily reset leveraged ETFs in volatile markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Direxion Daily TSLA Bull 2X Shares
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →
